ABCDEFGHIJKLMNOPQRSTUVW
1
Date of Product ApprovalProductFederal Register DatePRV Issuance URLPRV RecipientPRV Buyer or Redeeming Sponsor (if known)Payment (if known)PRV Transaction Date (if known)Transaction URLDIFF between PRV Issued Date and PRV Transaction Date
2
04/07/2009
Coartem (artemether/lumefantrine)
-https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022268s000_SumR.pdfNovartisNovartis---
3
12/28/2012Sirturo (bedaquiline)-https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/204384Orig1s000ltr.pdfJanssen (JNJ)Janssen (JNJ)---
4
02/14/2014VIMIZIM (elosulfase alfa)03/12/2014https://www.govinfo.gov/content/pkg/FR-2014-03-12/pdf/2014-05410.pdfBioMarin Pharmaceutical, IncRegeneron Ireland$67,500,00007/29/2014https://www.sec.gov/Archives/edgar/data/1048477/000119312514384895/d798950dex101.htm165
5
03/19/2014Impavido (miltefosine)-https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/204684Orig1s000ltr.pdfPaladin/KnightGilead$125,000,00011/19/2014https://www.biospace.com/article/knight-therapeutics-sells-priority-review-voucher-to-gilead-sciences-inc-for-us-125-million-cash-/245
6
03/10/2015UNITUXIN (dinutuximab)04/07/2015https://www.govinfo.gov/content/pkg/FR-2015-04-07/pdf/2015-08014.pdfUnited Therapeutics CorporationAbbVie$350,000,00008/19/2015https://www.sec.gov/Archives/edgar/data/1082554/000110465915060788/a15-18206_1ex99d1.htm162
7
03/17/2015CHOLBAM (cholic acid)04/07/2015https://www.govinfo.gov/content/pkg/FR-2015-04-07/pdf/2015-08016.pdfAsklepion/RetrophinSanofi$245,000,00005/22/2015https://www.sec.gov/Archives/edgar/data/1438533/000119312515201124/d932773dex21.htm66
8
09/04/2015Xuriden (uridine triacetate)09/29/2015https://www.govinfo.gov/content/pkg/FR-2015-09-29/pdf/2015-24640.pdfWellstat Therapeutics Corp
9
10/23/2015STRENSIQ (asfotase alfa)11/17/2015https://www.govinfo.gov/content/pkg/FR-2015-11-17/pdf/2015-29280.pdfAlexion PharmaceuticalsAlexion Pharmaceuticals---
10
12/08/2015KANUMA (sebelipase alfa)07/01/2019https://www.govinfo.gov/content/pkg/FR-2019-07-01/pdf/2019-13944.pdfAlexion Pharmaceuticals----
11
06/10/2016Vaxchora-https://www.fda.gov/vaccines-blood-biologics/vaccines/vaxchoraPaxVaxGilead$200,000,000-several reports
12
09/19/2016EXONDYS 51 (eteplirsen)10/17/2016https://www.govinfo.gov/content/pkg/FR-2016-10-17/pdf/2016-24947.pdfSarepta TherapeuticsGilead$125,000,00002/20/2017https://www.sec.gov/Archives/edgar/data/873303/000156459017008747/srpt-ex101_27.htm154
13
12/23/2016SPINRAZA (nusinersen)03/06/2017https://www.govinfo.gov/content/pkg/FR-2017-03-06/pdf/2017-04228.pdfBiogen
14
02/09/2017EMFLAZA (deflazacort)04/25/2017https://www.govinfo.gov/content/pkg/FR-2017-04-25/pdf/2017-08309.pdfMarathon Pharmaceuticals, LLCViiV Healthcare
15
04/27/2017Brineura (cerliponase alfa)06/26/2017https://www.govinfo.gov/content/pkg/FR-2017-06-26/pdf/2017-13236.pdfBiomarin Pharmaceuticals IncNovartis$125,000,00011/21/2017https://www.sec.gov/Archives/edgar/data/1048477/000156459018003114/bmrn-ex1047_294.htm208
16
08/29/2017Benznidazole-https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/209570Orig1s000ltr.pdfChemo ResearchNovo Nordisk
17
11/15/2017MEPSEVII (vestronidase alfa-vjbk)12/15/2017https://www.govinfo.gov/content/pkg/FR-2017-12-15/pdf/2017-27049.pdfUltragenyx PharmaceuticalNovartis$130,000,00012/18/2017https://www.sec.gov/Archives/edgar/data/1515673/000156459017025027/rare-ex991_6.htm33
18
12/19/2017
LUXTURNA (voretigene neparvovec)
01/02/2018https://www.govinfo.gov/content/pkg/FR-2018-01-02/pdf/2017-28256.pdfSpark TherapeuticsJazz Pharmaceuticals$110,000,00004/30/2018https://sparktx.com/press_releases/spark-therapeutics-sells-priority-review-voucher-for-110-million/132
19
02/12/2018SYMDEKO (tezacaftor/ivacaftor)03/29/2019https://www.govinfo.gov/content/pkg/FR-2019-03-29/pdf/2019-06138.pdfVertex Pharmaceutical
20
04/17/2018CRYSVITA (burosamab-twza)08/15/2018https://www.govinfo.gov/content/pkg/FR-2018-08-15/pdf/2018-17527.pdfUltragenyx Pharmaceutical, IncGilead$80,600,00006/01/2018http://ir.ultragenyx.com/node/12186/html45
21
05/01/2018KYMRIAH (tisagenlecleucel)09/11/2017https://www.govinfo.gov/content/pkg/FR-2017-09-11/pdf/2017-19130.pdfNovartis----
22
06/13/2018Moxidectin-https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/210867Orig1s000Ltr.pdfMedicines DevelopmentNovo Nordisk
23
06/25/2018
EPIDIOLEX (cannabidiol oral solution)
07/19/2018https://www.govinfo.gov/content/pkg/FR-2018-07-19/pdf/2018-15393.pdfGW Research LtdBiohaven Pharmaceutical$105,000,00003/15/2019https://www.sec.gov/Archives/edgar/data/1351288/000156459019016648/gwph-ex101_76.htm263
24
07/13/2018TPOXX (tecovirimat)04/01/2019https://www.govinfo.gov/content/pkg/FR-2019-04-01/pdf/2019-06145.pdfSIGA Technologies, IncEli Lilly$80,000,00011/01/2018https://www.sec.gov/Archives/edgar/data/1010086/000114036118042027/ex99_1.htm111
25
07/20/2018Krintafel-https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210795Orig1s000Approv.pdfGSKViiV Healthcare
26
10/05/2018REVCOVI (elapegademase-lvlr)10/25/2018https://www.govinfo.gov/content/pkg/FR-2018-10-25/pdf/2018-23308.pdfLeadiant Bioscience Inc
27
11/20/2018GAMIFANT (emapalumab-lzsg)12/13/2018https://www.govinfo.gov/content/pkg/FR-2018-12-13/pdf/2018-27043.pdfNovimmune/SobiAstraZeneca$95,000,00008/22/2019https://www.astrazeneca.com/media-centre/press-releases/2019/astrazeneca-agrees-to-buy-us-fda-priority-review-voucher-from-sobi-22082019.html275
28
02/13/2019Egaten-https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/208711Orig1s000ltr.pdfNovartis----
29
05/01/2019Dengvaxia-https://www.fda.gov/media/124402/downloadSanofi----
30
05/24/2019
ZOLGENSMA (onasemnogene abeparvovec-xioi)
06/24/2019https://www.govinfo.gov/content/pkg/FR-2019-06-24/pdf/2019-13356.pdfAveXis, Inc
31
08/14/2019Pretomanid-https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212862Orig1s000Approv.pdfTB Alliance
32
09/24/2019
JYNNEOS, (Smallpox and Monkeypox Vaccine, Live, Non-replicating)
10/09/2019https://www.govinfo.gov/content/pkg/FR-2019-10-09/pdf/2019-21984.pdfBavarian Nordic A/Sundisclosed$95,000,00012/17/2019http://www.bavarian-nordic.com/investor/news/news.aspx?news=588784
33
10/21/2019Trikafta-https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212273Orig1s000Approv.pdfVertex
34
12/12/2019VYONDYS 53 (golodirsen)01/23/2020https://www.govinfo.gov/content/pkg/FR-2020-01-23/pdf/2020-01059.pdfSarepta Therapeutics, IncVifor Pharma$108,100,00002/17/2020https://www.sec.gov/ix?doc=/Archives/edgar/data/873303/000156459020021905/srpt-10q_20200331.htm67
35
12/19/2019Ervebo-https://www.fda.gov/media/133757/downloadMerck----
36
37
38
max$350,000,000
39
min $67,500,000
40
average$136,080,000
41
median$110,000,000